Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) will be posting its quarterly earnings results on Wednesday, May 10th. Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last released its quarterly earnings results on Thursday, March 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.14). […]
/PRNewswire/ -- DelveInsight's FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors...
The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,050,000 shares, a growth of 17.6% from the March 15th total of 892,900 shares. Based on an average daily trading volume, of 84,200 shares, the days-to-cover […]
Next-generation immunotherapies market is expected to grow significantly during the forecast period (2023-2032) owing to the increasing number of cancer cases in the 7MM, accompanied by the